Slingshot members are tracking this event:

Aimmune (AIMT) Will Begin Enrollment for RAMSES Trial Designed to Build Real-World Experience with AR101 in Desensitization of Peanut Allergies in the Q2 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Update on Mar 15 2017: Initially expected to begin Q1 2017, RAMSES (Real-world AR101 Market-Supporting Experience Study) Planned to Start in the Second Quarter of 2017
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 11, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ramses Trial, Real-world Experience, Ar101, Peanut Allergies, Desensitization Of Peanut Allergies